1921
Volume 51, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
USD

Abstract

Abstract

A circumsporozoite protein (PfCSP) recombinant fusion protein, R32NSI, formulated with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane (Detox™) was administered to 12 volunteers. One volunteer had malaise and self-limited painful induration at the injection site after the second dose and declined further immunization. The other 11 volunteers tolerated the three doses of 1,230 µg of vaccine, but most complained of sore arms; in five cases the pain or malaise was severe enough to interfere with work or sleep. Two weeks after the third dose of vaccine, four of the 11 immunized volunteers had ≥ 14 µg/ml of antibodies to the repeat region of the PfCSP in their serum. Two of these four volunteers did not develop parasitemia when challenged by the bite of five mosquitoes carrying sporozoites. The seven volunteers with lower levels of antibodies and 11 of 11 controls developed parasitemia. These data are consistent with other studies, and indicate that vaccine-induced antibodies against the repeat region of PfCSP can prevent effective sporozoite infection of hepatocytes in humans. The challenge is to improve the immunogenicity of PfCSP-based vaccines, and to develop methods for including PfCSP peptides as components of multitarget malaria vaccines.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.1994.51.603
1994-11-01
2017-09-20
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.1994.51.603
Loading

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error